Literature DB >> 21124333

Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.

Yoshiyuki Morishita1, Shiho Hanawa, Junko Chinda, Osamu Iimura, Sadao Tsunematsu, Eiji Kusano.   

Abstract

The renin-angiotensin-aldosterone system (RAAS) has pivotal roles in the pathogenesis of hypertension in hemodialysis-dependent chronic kidney disease (HDD-CKD) patients. Activated RAAS also increases inflammatory mediators by directly increasing proinflammatory gene expression and by putting oxidative stress on the vascular endothelium. Both hypertension and inflammation are major risk factors for cardiovascular disease (CVD) in HDD-CKD patients. In this study, we assessed the efficacy of a direct renin inhibitor, aliskiren, on blood pressure (BP) and CVD predictive biomarkers, such as brain natriuretic peptide (BNP), high-sensitivity C-reactive protein (hs-CRP) and diacron-reactive oxygen metabolite (d-ROM). A total of 30 hypertensive HDD-CKD patients were assigned to receive aliskiren (150 mg) orally once daily with their existing antihypertensives. After 8 weeks, aliskiren treatments reduced systolic blood pressure (SBP) from 169.0±20.1 to 153.7±19.6 mmHg (P<0.001) and diastolic blood pressure (DBP) from 78.1±12.0 to 73.0±13.6 mmHg (P=0.048). RAAS was suppressed by aliskiren treatment as follows: PRA (from 3.6±4.0 to 1.0±1.5 ngml(-1)h(-1) (P=0.004)), angiotensin I (from 1704.0±2580.9 to 233.7±181.0 pgml(-1) (P=0.009)), angiotensin II (from 70.2±121.5 to 12.4±11.5 pgml(-1) (P=0.022)) and aldosterone (from 107.9±148.0 to 73.1±34.6 pgml(-1) (NS)). The biomarkers for CVD were inhibited by aliskiren: BNP (from 362.5±262.1 to 300.0±232.0 pgml(-1) (P=0.043)), hS-CRP (from 6.2±8.1 to 3.5±3.7 mgl(-1) (P=0.022)) and d-ROM (from 367.0±89.8 to 328.3±70.9 U.CARR (P=0.022)). The inhibition levels of biomarkers for CVD by aliskiren did not correlate with the decreased levels of SBP and DBP. These results suggested that aliskiren was effective for BP control and may have cardiovascular protective effects in hypertensive HDD-CKD patients.
© 2011 The Japanese Society of Hypertension All rights reserved

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21124333     DOI: 10.1038/hr.2010.238

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  14 in total

Review 1.  Immunologic Effects of the Renin-Angiotensin System.

Authors:  Steven D Crowley; Nathan P Rudemiller
Journal:  J Am Soc Nephrol       Date:  2017-02-01       Impact factor: 10.121

2.  Neutrophil gelatinase-associated lipocalin levels associated with cardiovascular disease in chronic kidney disease patients.

Authors:  Fumihiko Furuya; Hiroki Shimura; Hiroshi Yokomichi; Kazuya Takahashi; Daiichiro Akiyama; Chikako Asakawa; Ayako Okamura; Ai Motosugi; Kazutaka Haraguchi; Zentaro Yamagata; Tetsuro Kobayashi
Journal:  Clin Exp Nephrol       Date:  2013-12-12       Impact factor: 2.801

Review 3.  Direct renin inhibition in chronic kidney disease.

Authors:  Frederik Persson; Peter Rossing; Hans-Henrik Parving
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

Review 4.  Mechanism by which chronic kidney disease causes cardiovascular disease and the measures to manage this phenomenon.

Authors:  Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2011-06-01       Impact factor: 2.801

5.  Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study.

Authors:  Satoru Kuriyama; Keitaro Yokoyama; Yoichiro Hara; Naoki Sugano; Takashi Yokoo; Tatsuo Hosoya
Journal:  Clin Exp Nephrol       Date:  2013-11-20       Impact factor: 2.801

6.  Emerging concept of anti-hypertensive therapy based on ambulatory blood pressure profile in chronic kidney disease.

Authors:  Kouichi Tamura; Tomohiko Kanaoka; Masato Ohsawa; Sona Haku; Kengo Azushima; Akinobu Maeda; Toru Dejima; Hiromichi Wakui; Motoko Ozawa; Atsu-Ichiro Shigenaga; Yoshiyuki Toya; Satoshi Umemura
Journal:  Am J Cardiovasc Dis       Date:  2011-09-08

7.  Aliskiren suppresses the renin-angiotensin-aldosterone system and reduces blood pressure and albuminuria in elderly chronic kidney disease patients with hypertension.

Authors:  Yoshiyuki Morishita; Toshihiro Yasui; Akihiko Numata; Akira Onishi; Kenichi Ishibashi; Eiji Kusano
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-09-21

8.  Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients.

Authors:  Yoshiyuki Morishita; Minami Watanabe; Shiho Hanawa; Osamu Iimura; Sadao Tsunematsu; Kenichi Ishibashi; Eiji Kusano
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-03-21

9.  Systematic Review and Meta-Analysis of Renin-Angiotensin-Aldosterone System Blocker Effects on the Development of Cardiovascular Disease in Patients With Chronic Kidney Disease.

Authors:  Katsunori Yanai; Kenichi Ishibashi; Yoshiyuki Morishita
Journal:  Front Pharmacol       Date:  2021-07-02       Impact factor: 5.810

10.  Direct Renin inhibitor: aliskiren in chronic kidney disease.

Authors:  Yoshiyuki Morishita; Eiji Kusano
Journal:  Nephrourol Mon       Date:  2012-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.